^
Association details:
| Biomarker: | ETV6-NTRK3 fusion |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile
Published date:
10/12/2022
Excerpt:
A woman presented to medical oncology with almost 4 years of untreated, slowly progressing, triple negative metastatic breast cancer to the lung....Identification of ETV6--NKRT3 fusion allowed for treatment with larotrectinib, a tyrosine kinase inhibitor specifically indicated for secretory breast carcinoma. After 3 months, she experienced a partial response.
DOI:
10.1136/bcr-2022-251656
